Compliance with antiviral therapy in patients with chronic hepatitis B
-
摘要: 目的研究慢性乙型肝炎患者的服药依从性并分析其影响因素。方法采用回顾性队列研究,选取2011年1月1日-2016年12月31日广州市第八人民医院门诊治疗的3732例慢性乙型肝炎患者,通过医院信息系统收集其人口学特征、就诊医生资料、取药信息、检查信息,依据药物持有率将患者分为良好依从性组(n=2346)与不良依从性组(n=1386),采用χ2检验比较两组间的人口学特征和诊疗情况,影响因素分析采用两水平稳健Poisson方差成分模型。结果慢性乙型肝炎患者药物持有率为0. 789±0. 269,持有率在0. 8以上的良好依从性患者占比62. 86%。多因素分析结果显示,结算方式、治疗时间、医生职称及用药模式是良好依从性的影响因素(P值均<0. 05)。在控制了其他协变量后,医保患者其良好依从性比自费患者高0. 119倍;良好依从性总体呈下降趋势,第2~5年的良好依从性分别是第1年的84. 7%、77. 3%、78. 5%、65. 9%;副主任医师负责的患者,其良好依从性比主治及住院医师负责的患者高0. 249倍;服用替比夫定的患者其良好依从性比服用恩替卡韦的患者高0...Abstract: Objective To investigate the medication compliance in patients with chronic hepatitis B and related influencing factors. Methods A retrospective cohort study was conducted for 3732 patients with chronic hepatitis B who were treated in the outpatient service of Guangzhou Eighth People's Hospital from January 1,2011 to December 31,2016,and related clinical data were collected from the hospital's information system,including demographic features,information of the physician in charge,medication information,and examination data. According to the medication possession ratio( MPR),the patients were divided into good compliance group with 2346 patients and poor compliance group with 1386 patients. The chi-square test was used to compare demographic features,diagnosis,and treatment between the two groups,and the two-level robust Poisson regression model was used to analyze influencing factors. Results The patients with chronic hepatitis B had an MPR of 0. 789 ± 0. 269,and 62. 86% of the patients with good compliance had an MPR of > 0. 8. The multivariate analysis showed that method of payment,time of treatment,physician's professional title,and pattern of medication were the influencing factors for compliance( all P < 0. 05). After the control of the other covariants,the proportion of patients with good compliance among the patients covered by medical insurance was 0. 119 times higher than that among the self-paying patients. The proportion of patients with good compliance tended to decrease in general,and the proportion of patients with good compliance in the 2th-5th years was15. 3%,22. 7%,21. 5%,and 34. 1%,respectively,lower than that in the first year. The proportion of patients with good compliance among the patients under the charge of an associate chief physician was 0. 249 times higher than that among the patients under the charge of an attending physician or a resident. The proportion of patients with good compliance among the patients receiving telbivudine was 0. 120 times higher than that among the patients taking entecavir. Conclusion Medication compliance of patients with chronic hepatitis B is closely associated with medical insurance,time of treatment,professional title of the physician in charge,and pattern of medication. The patients without medical insurance should be encouraged to purchase medical insurance. It is important to strengthen health education among patients with chronic hepatitis B and promote them to follow the guidelines for the treatment of chronic hepatitis B.
-
Key words:
- hepatitis B,chronic /
- medication adherence /
- influencing factor
-
[1] WHO. Global hepatitis report 2017[EB/OL].[2018-01-10]http://www. who. int/hepatitis/publications/global-hepatitis-report2017/en/. [2] WU XF,LI YF,ZHANG C,et al. Influencing factors for compliance with antiviral therapy with nucleos(t)ide analogues in patients with chronic hepatitis B[J]. J Clin Hepatol,2019,35(10):2194-2199.(in Chinese)吴小凤,李玉芳,张驰,等.慢性乙型肝炎患者核苷(酸)类似物抗病毒治疗依从性的影响因素分析[J].临床肝胆病杂志,2019,35(10):2194-2199. [3] CHOTIYAPUTTA W,OBERHELMAN K,HONGTHANAKORN C,et al. Correlation between self-reported adherence to nucleos(t)ide analog(NUC)therapy for chronic hepatitis B and virological breakthroughs(VBT). AASLD[J]. Hepatology,2010,52:542A. [4] Chinese Society of Hepatology,Chinese Medical Association.Chinese Society of Infectious Diseases,Chinese Medical Association; The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会.中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960. [5] PETERSON AM,NAU DP,CRAMER JA,et al. A checklist for medication compliance and persistence studies using retrospective databases[J]. Value Health,2007,10(1):3-12. [6] LUMLEY T,KRONMAL R,MA S. Relative risk regression in medical research:Models,contrasts,estimators,and algorithms[R]. Bepress,2006:293. [7] QIU Q. Effect of the partial reimbursement implementation of antivirals for hepatitis B virus in Beijing:Comparative effectiveness analysis and cost-effectiveness analysis based on a retrospective cohort study[D]. Beijing:Peking Union Medical College,2015.(in Chinese)邱倩.北京市新医疗保险政策实施后慢性乙型肝炎病人不同抗病毒治疗方案比较效果研究及卫生经济学评价[D].北京:北京协和医学院,2015. [8] ZHANG LM,SHA L,LI NN,et al. Treatment compliance and its influencing factors in patients with chronic hepatitis B[J].Mod Med J,2016,44(1):7-10.(in Chinese)张利漫,沙莉,李楠楠,等.慢性乙型肝炎患者治疗依从性现状及其影响因素分析[J].现代医学,2016,44(1):7-10. [9] SHUBBER Z,MILLS EJ,NACHEGA JB,et al. Patient-reported barriers to adherence to antiretroviral therapy:A systematic review and meta-analysis[J]. PLo S Med, 2016,13:e1002183. [10] HUA L,SHI J,SHA L,et al. Using health belief model education to improve the treatment compliance of patients with chronic hepatitis B[J]. J Clin Med Pract,2014,18(22):124.(in Chinese)华琳,史洁,沙莉,等.运用健康信念模式教育提高慢性乙型肝炎患者治疗依从性的研究[J].实用临床医药杂志,2014,18(22):124. [11] LU SJ,LI Z. Effect of the application of we chat platform on the treatment compliance and satisfaction of chronic hepatitis B patients[J]. Hosp Admin J Chin PLA,2016,23(7):668-670.(in Chinese)鲁松景,李珍.基于微信平台增强慢性乙型肝炎患者的治疗依从性和满意度[J].解放军医院管理杂志,2016,23(7):668-670. [12] KAN Q,WEN J,XUE R. Discrimination against people with hepatitis B in China[J]. Lancet,2015,386(9990):245-246. 期刊类型引用(20)
1. 彭语晨,邬小萍. 慢性乙型肝炎临床治愈的研究现状与前景. 西南医科大学学报. 2025(01): 27-31 . 百度学术
2. 李斌华,陈小勇,李雷. 加强门静脉高压症的临床管理,促进失代偿性肝硬化再代偿. 肝脏. 2025(02): 262-265 . 百度学术
3. 廖敏,余纳,宋华锋,李粤平,左璇. 当前国内传染病医保支付方式的现状研究. 中国公共卫生管理. 2025(01): 42-46 . 百度学术
4. 杨晶艳,刘丽萍,陈梅春,周双红. 慢性乙型肝炎患者服药依从性的影响因素分析. 健康研究. 2024(02): 167-171+176 . 百度学术
5. 张思慧,崔富强. 对慢性HBV感染者全部治疗策略的卫生经济学考量. 中华肝脏病杂志. 2024(05): 406-410 . 百度学术
6. 李斌华,谢峰,闫雪华,陈小勇,李雷,王文青. 综合医院MDT模式下肝硬化门静脉高压症患者全病程管理的探讨. 临床医学研究与实践. 2024(36): 182-185 . 百度学术
7. 唐丽娟,窦婉. 整合式心理干预对乙型肝炎患者病耻感、心理调适及治疗依从性的影响. 中国健康心理学杂志. 2023(03): 372-376 . 百度学术
8. 罗发燕,陈铁霞,罗平平,诸伟红. 慢性乙型肝炎患者服药依从性调查. 预防医学. 2023(11): 966-969+974 . 百度学术
9. 王晓燕,阚延婷. 艾米替诺福韦治疗联合纽曼系统模式护理干预对慢性乙型肝炎患者抗病毒治疗依从性的影响分析. 现代医学与健康研究电子杂志. 2023(22): 125-128 . 百度学术
10. 蔡冬梅,胡婷婷. 网络互动式健康教育对中青年乙型肝炎患者疾病认知及治疗依从性的影响. 中国医药导报. 2022(04): 166-169 . 百度学术
11. 吕卉. 慢性病毒性肝炎患者治疗依从性的相关影响因素分析. 当代护士(上旬刊). 2022(01): 58-60 . 百度学术
12. 王玉美,李雪,范琪琪,王爱敏. 青岛慢性乙型肝炎患者抗病毒治疗服药依从性现状及影响因素分析. 社区医学杂志. 2022(04): 228-232 . 百度学术
13. 房卫. 基于微信平台延伸护理对慢性乙型肝炎患者遵医行为及生存质量的影响. 基层医学论坛. 2022(12): 142-144 . 百度学术
14. 邓娜娜,周美芳. "5个时刻法"用药宣教应用于慢性乙型肝炎抗病毒治疗中的效果. 国际护理学杂志. 2022(06): 1104-1107 . 百度学术
15. 林莉莉,陈素绸. 医院—家庭一体化管理策略对慢性乙型肝炎患者负性情绪及生活质量的影响. 中国医药指南. 2022(30): 53-56 . 百度学术
16. 徐新闻,黎碧云. 药学服务对提高慢性乙型肝炎患者用药依从性的效果影响分析. 黑龙江医药. 2022(06): 1294-1296 . 百度学术
17. 沈璐,周翠梅,张静,薛继华,李惠萍. 慢性乙型肝炎患者抗病毒治疗知信行量表的编制及信效度检验. 中国健康教育. 2021(03): 217-221 . 百度学术
18. 杨玲. 影响慢性乙型肝炎患者服药依从性相关危险因素及其干预措施分析. 内蒙古医学杂志. 2021(07): 836-838 . 百度学术
19. 张伯锋. 解毒利湿方治疗慢性乙型肝炎随机对照试验的系统评价. 中医临床研究. 2021(16): 14-16 . 百度学术
20. 任菲菲,姚雷娜. 慢性乙型肝炎患者用药依从性个体化预测模型的建立与验证. 传染病信息. 2021(05): 411-416 . 百度学术
其他类型引用(3)
-